DelveInsight의 "알레르기 비결막염 - 시장 인사이트, 역학, 시장 예측 - 2034" 보고서는 알레르기 비결막염에 대한 깊은 이해, 미국, EU 4개국(독일, 프랑스, 이탈리아, 스페인), 영국 및 일본의 과거 및 예측 역학 및 알레르기 비결막염 본 보고서에서는 현재의 치료실천, 신흥약제, 개별요법 시장 점유율, 2020년부터 2034년까지 주요 7개국 알레르기 비결막염 시장 규모의 현황과 예측을 제공합니다. 또한 현재의 알레르기 비결막염 치료 실천/알고리즘과 암멧 의료 요구를 망라하여 최적의 기회를 선정함과 동시에 시장의 잠재성을 평가합니다.
DelveInsight's "Allergic Rhino-Conjunctivitis - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of allergic rhino-conjunctivitis, historical and forecasted epidemiology as well as allergic rhino-conjunctivitis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The allergic rhino-conjunctivitis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM allergic rhino-conjunctivitis market size from 2020 to 2034. The report also covers current allergic rhino-conjunctivitis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
Allergic Rhino-Conjunctivitis Overview
Allergic rhino-conjunctivitis is an allergen-induced inflammatory response. Allergic rhino-conjunctivitis is the result of IgE-mediated allergy and nasal mucosa inflammation. IgE is produced in the lymphoid tissues and locally in response to common environmental allergens. When allergens bind to mast-cell-bound IgE, mast-cell degranulation occurs and release of a myriad of biochemical mediators. Histamine is the key player in the acute allergic response. The non-infective, seasonal (SAR) and perennial allergic rhino-conjunctivitis (PAR) are the most common types of allergic rhino-conjunctivitis. Histamine is a well-known mediator responsible for the signs and symptoms of SAR but many other mediators including leukotrienes and prostaglandin D2 are involved. SAR is caused by allergens released by tree, grass or weed pollination (and spores and moulds), whereas PAR results from allergens such as animal dander, dust mites and less frequently from allergens such as cockroaches or mould spores. Symptoms are both nasal and non-nasal. The most prominent nasal symptoms are itching, sneezing, rhinorrhoea and congestion. Non-nasal symptoms commonly associated with allergic rhinitis include tearing, eye itching and redness.
Allergic Rhino-Conjunctivitis Diagnosis
Allergic rhino-conjunctivitis is diagnosed through medical history, symptoms evaluation, physical examination, allergy testing (skin prick, Ig test or blood test), and, if necessary, elimination and challenge tests or nasal endoscopy. The diagnosis of rhino-conjunctivitis is established by the concordance between the symptoms and the diagnostic tests. The concurrent occurrence of nasal and eye symptoms is a key feature of rhinoconjunctivitis. Common symptoms include runny nose, nasal congestion, sneezing, nasal itching, watery eyes, eye swelling, and ocular itching. Patients with allergic conjunctivitis often exhibit distinct facial features, such as a horizontal crease across the bridge of the nose, known as the "allergic salute," caused by frequent nose rubbing.
Allergic Rhino-Conjunctivitis Treatment
There are a number of treatment options for allergic rhino-conjunctivitis. These treatment options are used to treat a specific patient's that depends on the type of allergen and patient's overall health. Treatment involves a multifaceted approach to address symptoms and provide long-term management. One crucial aspect is allergen avoidance. Identifying specific allergens, such as pollen, dust mites, pet dander, allows individuals to take measures to minimize exposure. This includes using air purifiers, employing allergen-proof bedding, and maintaining a clean living environment. Allergic rhino-conjunctivitis is treated with allergen avoidance, antihistamines, nasal corticosteroids, eye drops, mast cell stabilizer, and immunotherapy if needed. This combination approach helps alleviate symptoms and provides long-term relief for allergy sufferers. Antihistamines, available over-the-counter or as prescription medications, help alleviate itching, sneezing, and runny nose. Nasal corticosteroid sprays, like fluticasone and mometasone, are effective in reducing nasal congestion and inflammation. Decongestants, both oral and nasal, provide temporary relief from congestion. Immunotherapy is a long-term approach that can be considered for moderate to severe allergies. Subcutaneous Immunotherapy (SCIT), commonly known as allergy shots used in allergic rhino-conjunctivitis.
As the market is derived using the patient-based model, the allergic rhino-conjunctivitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of allergic rhino-conjunctivitis, diagnosed prevalent cases of allergic rhino-conjunctivitis, age-specific cases of allergic rhino-conjunctivitis, and treatable cases of allergic rhino-conjunctivitis in the 7MM covering the US, EU4 (Germany, France, Italy, Spain) and the UK, and Japan from 2020 to 2034.
The drug chapter segment of the allergic rhino-conjunctivitis report encloses a detailed analysis of the marketed and the late, mid, and early stage (Phase III, Phase II, and Phase I/II) pipeline drugs. The marketed drugs segment encloses drugs such as GRASTEK, RAGWITEK, ODACTRA, and others. The drug chapter also helps understand the allergic rhino-conjunctivitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, and the latest news and press releases.
Marketed Drugs
ODACTRA: ALK-Abello
ODACTRA is an allergen extract indicated as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites or by positive skin testing to licensed house dust mite allergen extracts. ODACTRA is an allergy immunotherapy (AIT) tablet which dissolves under the tongue and helps patients reduce their allergy symptoms and their reliance on symptomatic medication. The FDA approval is an important step in ALK's efforts to make all its respiratory tablets available for all age groups - children, adolescents, and adults - in all relevant markets.
In February 2025, ALK announced that the US Food and Drug Administration (FDA) had approved ALK's ODACTRA tablet for use in young children with HDM allergy. ODACTRA is now indicated to treat HDM-induced allergic rhinitis, with or without conjunctivitis, in children aged five through 11, in addition to patients aged 12 through 65.
ODACTRA was first approved in the United States in 2017 for adults aged 18-65 for treating house dust mite-induced allergic rhinitis, with or without conjunctivitis. The FDA expanded ODACTRA's approval in 2023 to include adolescents aged 12-17 years.
RAGWITEK: Merck and ALK-Abello
RAGWITEK is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. RAGWITEK is approved for use in persons 5 through 65 years of age.
In April 2021, FDA approved ALK's RAGWITEK tablet for sublingual use as immunotherapy for children and adolescents (5-17 years age) with short ragweed pollen-induced allergic rhinitis with or without conjunctivitis.
In April 2014, FDA had given approval to Merck's RAGWITEK (Short Ragweed Pollen Allergen Extract) sublingual tablet as immunotherapy to treat short ragweed pollen-induced allergic rhinitis with or without conjunctivitis in adults. The approval was based on the efficacy of RAGWITEK was supported by two Phase III clinical studies over a single ragweed pollen season in patients 18 through 50 years of age.
Emerging Drugs
MM09: Immunotek
Immunotek is conducting many trials around MM09. MM09 is a purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) for treatment approach related to mild to moderate asthma and rhinitis/rhino-conjunctivitis. MM09 is an allergoid-mannan conjugates subcutaneous. The company is currently conducting a Phase III clinical trial (NCT05400811), which is not yet recruiting, to evaluate the efficacy and safety of a treatment for HDM-induced allergic asthma and rhinitis/rhinoconjunctivitis.
Also, the company had initiated another Phase III trial (NCT04435990) to determine the efficacy and safety of subcutaneous immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without asthma, sensitised to Dermatophagoides pteronyssinus and /or Dermatophagoides farinae.
Drug Class Insights
Allergen Immunotherapy (AIT)
Allergen immunotherapy is a treatment that can help prevent allergic reactions to substances like grass pollen, house dust mites, and bee venom. It's the only treatment that can modify the course of allergic diseases. AIT can be administered in several ways, including subcutaneous immunotherapy (SCIT), sublingual immunotherapy (SLIT) intranasal, and epicutaneous. AIT is usually recommended for people who are selectively sensitive to several allergens. It's not advised for people with uncontrolled asthma, as there's a higher risk of systemic reactions.
For many patients with allergic rhino-conjunctivitis, allergen immunotherapy (AIT) remains the current standard of care. While numerous studies have demonstrated improved time to symptom control and overall quality of life compared to placebo, emerging therapeutic strategies are now exploring targeted biologics, including monoclonal antibodies that enhance treatment specificity and effectiveness.
Among the limited pipeline activity, Immunotek appears to be the most active company in this space, with ongoing trials listed on ClinicalTrials.gov despite no recent updates on its official website or pipeline disclosures. Additionally, Blueprint Medicines is evaluating BLU-808 in Canada for allergic rhino-conjunctivitis; however, with the company currently prioritizing regulatory approval for BLU-808 in Chronic Spontaneous Urticaria (CSU) in the US, it is likely that an Investigational New Drug (IND) filing for US investigation in allergic rhino-conjunctivitis may follow.
To summarize, the scarce pipeline in allergic rhino-conjunctivitis highlights a significant opportunity for innovation and market entry. As several new therapies gradually emerge, the treatment paradigm is expected to evolve. This presents a strong opportunity for companies to address the substantial unmet medical need, particularly given the high rate of treatment switching and reliance on multi-drug regimens. Physician enthusiasm for novel, more effective therapies is likely to further drive demand, making this a strategically attractive area for pipeline expansion and investment.
The pipeline of allergic rhino-conjunctivitis is not very robust. There are a few key players actively involving in the development of promising products in allergic rhinitis and allergic conjunctivitis such as Immunotek, and others.
This section highlights the anticipated uptake of potential drugs projected to enter the market between 2025 and 2034. The current treatment landscape for allergic rhino-conjunctivitis presents a substantial opportunity, as existing regimens largely focus on symptom management rather than disease modification. The current pipeline remains limited, highlighting a clear unmet need for more innovative and disease-modifying treatment options. This gap presents a strong opportunity for pharmaceutical investment, as patients and physicians continue to seek alternatives beyond conventional symptom-relief therapies. The increasing adoption of these innovative treatments reflects the commitment of physicians, researchers, and the broader healthcare community to improve patient outcomes. This evolving treatment paradigm underscores the impact of scientific advancement, cross-sector collaboration, and the collective effort to address a long-standing unmet need in allergic rhino-conjunctivitis.
Allergic Rhino-Conjunctivitis Pipeline Development Activities
The report provides insights into therapeutic candidates in Phase III, Phase II, and Phase I/II. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for allergic rhino-conjunctivitis emerging therapy.
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on allergic rhino-conjunctivitis 's evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including physician, and others.
Delveinsight's analysts connected with 15+ KOLs to gather insights; however, interviews were conducted with 05+ KOLs in the 7MM. Centers such as -Tottori University in Japan, University of Toyama in Japan, University of Tennessee Health Science Center in the US, University Hospital Dresden in Germany, and were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or allergic rhino-conjunctivitis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.
Conjoint Analysis analyses multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyse the effectiveness of therapy.
In efficacy, the trial's primary and secondary outcome measures are evaluated.
Further, the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed, and this clearly explains the drug's side effects in the trials. In addition, the scoring is also based on the probability of success and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
Globally, allergic rhino-conjunctivitis patient families spend an essential proportion of their household income on allergic rhino-conjunctivitis care. Allergic rhino-conjunctivitis patients have to face a huge economic burden alone without any healthcare coverage or proper reimbursement policies.
Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.